These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].
    Author: Dong HL, Sui YF, Ye J, Li ZS, Qu P, Zhang XM, Chen GS, Lu SY.
    Journal: Zhonghua Yi Xue Za Zhi; 2003 Jun 25; 83(12):1080-3. PubMed ID: 12899783.
    Abstract:
    OBJECTIVE: To predict, synthesize, and identify HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitopes of the tumor the novel antigen MAGE-n. METHODS: Long-distance prediction system SYFPEITHI combined with polynomial method was used to predict the HLA-A2-restricted CTL epitopes of the tumor antigen MAGE-n. The candidate epitopes were synthesized with solid phase strategies, purified with reverse phase high-performance liquid chromatography and identified by mass spectrometry, The binding affinity and biding stability of the synthesized peptides were examined by cellular competition-based HLA-A2 peptide binding assay, T2 peptide stabilization assay, and peptide-major histocompatibility complex dissociation assay. RESULTS: Five HLA-A2-restricted CTL epitopes of MAGE-n were selected: The epitopes QLVFGIEVV (159-167), IMPKTGGLI (195-203), and FLIIVLMI (201-209) with high HLA-A2 binding affinity (LC(50) < 15 micro mol/L) and binding stability (DT(50) > 6 h) were selected as candidate epitopes for further study in immunotherapy for tumor. CONCLUSION: Epitope prediction combined with epitope reconstruction improves the study of HLA-A2-restricted CTL epitopes of the tumor antigen MAGE-n. The selected epitopes of MAGE-n may be used in the design of therapeutic peptide vaccine for hepatocellular carcinoma.
    [Abstract] [Full Text] [Related] [New Search]